Causes of Parkinson's disease

From Wikipedia, the free encyclopedia

Parkinson's disease (PD) is a complicated neurodegenerative disease that progresses over time and is marked by bradykinesia, tremor, and stiffness. As the condition worsens, some patients may also experience postural instability.[1] Parkinson's disease (PD) is primarily caused by the gradual degeneration of dopaminergic neurons in the region known as the substantia nigra along with other monoaminergic cell groups throughout the brainstem,[2] increased activation of microglia, and the build-up of Lewy bodies and Lewy neurites, which are proteins found in surviving dopaminergic neurons.[3]

Because the etiology of about 80% of PD cases is unknown, they are classified as idiopathic, whereas the other 20% are thought to be genetic. PD risk is increased by variations in the genetic mix of specific genes.[4] Research has indicated that the risk of Parkinson's disease (PD) is increased by mutations in the genes encoding leucine-rich repeat kinase 2 (LRRK2), Parkinson's disease-associated deglycase (PARK7), PRKN, PINK1, or SNCA (alpha-synuclein).[5][6]

Exposure to pesticides, metals, solvents, and other toxicants has been studied as a factor in the development of Parkinson's disease.[7]

Genetic factors[edit]

PDB rendering of Parkin (ligase)

Traditionally, Parkinson's disease has been considered a non-genetic disorder. However, around 15% of individuals with PD have a first-degree relative who has the disease.[8] At least 5–15% of cases are known to occur because of a mutation in one of several specific genes, transmitted in either an autosomal-dominant or autosomal-recessive pattern.[9]

Mutations in specific genes have been conclusively shown to cause PD. A large number of these genes are linked to translation.[10][11] Genes which have been implicated in autosomal-dominant PD include PARK1 and PARK4, PARK5, PARK8, PARK11 and GIGYF2 and PARK13 which code for alpha-synuclein (SNCA), UCHL1, leucine-rich repeat kinase 2 (LRRK2 or dardarin) (LRRK2 and Htra2 respectively[9][12] Genes such as PARK2, PARK6, PARK7 and PARK9 which code for parkin (PRKN), PTEN-induced putative kinase 1 (PINK1), DJ-1 and ATP13A2 respectively have been implicated in the development of autosomal-recessive PD[9][13][14] Furthermore, mutations in genes including those that code for SNCA, LRRK2 and glucocerebrosidase (GBA) have been found to be risk factors for sporadic PD[15] In most cases, people with these mutations will develop PD. With the exception of LRRK2, however, they account for only a small minority of cases of PD.[16] The most extensively studied PD-related genes are SNCA and LRRK2.

At least 11 autosomal dominant and nine autosomal recessive gene mutations have been implicated in the development of PD. The autosomal dominant genes include SNCA, PARK3, UCHL1, LRRK2, GIGYF2, HTRA2, EIF4G1, TMEM230, CHCHD2, RIC3, and VPS35. Autosomal recessive genes include PRKN, PINK1, DJ-1, ATP13A2, PLA2G6, FBXO7, DNAJC6, SYNJ1, and VPS13C. Some genes are X-linked or have unknown inheritance pattern; those include USP24, PARK12, and PARK16. A 22q11 deletion is known to be associated with PD.[17][18] An autosomal dominant form has been associated with mutations in the LRP10 gene.[19][20]

SNCA gene[edit]

The role of the SNCA gene is significant in PD because the alpha-synuclein protein is the main component of Lewy bodies, which appear as a primary biomarker in the disease.[9][21] Missense mutations of the gene (in which a single nucleotide is changed), and duplications and triplications of the locus containing it have been found in different groups with familial PD.[9] Level of alpha-synuclein expression correlates with disease onset and progression, with SNCA gene triplication advancing earlier and faster than duplication.[22] Missense mutations in SNCA are rare.[9] On the other hand, multiplications of the SNCA locus account for around 2% of familial cases.[9] Multiplications have been found in asymptomatic carriers, which indicate that penetrance is incomplete or age-dependent.[9]

LRRK2 gene[edit]

The LRRK2 gene (PARK8) encodes for a protein called dardarin. The name dardarin was taken from a Basque word for tremor, because this gene was first identified in families from England and the north of Spain.[16] A significant number of autosomal-dominant Parkinson's disease cases are associated with mutations in the LRRK2 gene[23] Mutations in LRRK2 are the most common known cause of familial and sporadic PD, accounting for approximately 5% of individuals with a family history of the disease and 3% of sporadic cases.[9][16] There are many different mutations described in LRRK2, however unequivocal proof of causation only exists for a small number.[9] Mutations in PINK1, PRKN, and DJ-1 may cause mitochondrial dysfunction, an element of both idiopathic and genetic PD.[22] Of related interest are mutations in the progranulin gene that have been found to cause corticobasal degeneration seen in dementia.[24] This could be relevant in PD cases associated with dementia.[24]

GBA gene[edit]

Mutations in GBA are known to cause Gaucher's disease.[9] Genome-wide association studies, which search for mutated alleles with low penetrance in sporadic cases, have now yielded many positive results.[25] Mendelian genetics are not strictly observed in GBA mutations found in inherited parkinsonism.[26] Incidentally, both gain-of-function and loss-of-function GBA mutations are proposed to contribute to parkinsonism through effects such as increased alpha-synuclein levels.[26] In patients with Parkinson's disease, the OR for carrying a GBA mutation was 5·43 (95% CI 3·89–7·57), confirming that mutations in this gene are a common risk factor for Parkinson's disease.[26]

Genes underlying familial Parkinson's disease[edit]

Genes underlying familial PD
HGNC symbol Gene Locus Function Mutations Clinical Presentations Neuropathology Age at onset Inheritance
PARK1/PARK4[27] SNCA[28] (α-synuclein) 4q21[29] Unknown synaptic function Duplications Idiopathic PD; some postural tremor; slow progression LBs Mid 20s – 30 Dominant
SNCA 4q22[29] instructions for making a small protein called alpha-synuclei[30]

may play a role in maintaining supply of synaptic vesicles in presynaptic terminals;

may regulate release of dopamine[30]

Triplications PD (Parkinson's Disease); PD with dementia;diffuse LBs disease;aggressive course; can develop cognitive dysfunction, autonomic failure, and myoclonus[31] LBs and Lewy neurites; ± glial inclusions; hippocampal CA2 and CA3 loss Mid 20s – 30s
A53T, A30P E46K[32][33] Idiopathic PD; early on setparkinsonism and diffuse LBs LBs and LNs; ± tau inclusions; amyloid plaques 30–60
PARK2[27] Parkin[34] E3 ubiquitin ligase[35] 200+ possible mutations including:[35]

- Inactivating somatic mutations

- Frequent intragenic deletions

Early on set Parkinsonism; slow progression PD variable presence of LBs Juvenile to 40 Recessive
PARK5[27] UCHL1 deubiquitinating enzyme Missense: Ile93Met[36] PD; late on set parkinsonism Unknown; various abnormal protein aggregations 30–50 Dominant
PARK6[27] PINK1[37] mitochondrial Ser-Thr Kinase 40+ mutations[37]

-Mostly point mutations

-Deletions on C-terminus Kinase domain

Parkinsonism Unknown 30–50 Recessive
PARK7[27] DJ-1[38] oxidative stress response? -10 point mutations including C46A, C53A, C106 & WT regions[38]

- Large deletion in L166P

Early onset Parkinsonism Unknown 20–40 Recessive
PARK8[27] LRRK2 (dardarin) 12q12[39] unknown protein kinase G2019S most common[40] late-onset Parkinson's Disease[41] Diffuse LBs; LNs; ± tau inclusions; ± amyloid plaques 40–60 Dominant

Environmental factors[edit]

Exposure to pesticides, metals, solvents, and other toxicants has been studied as a factor in the development of Parkinson's disease.[7] No definitive causal relationship has yet been established. Recent studies also reveal that individuals that sustain mild head injuries (concussions) also have an increased risk of acquiring the disease.[42][43] As discussed below, exercise and caffeine consumption are known to help decrease the risks of acquisition.

Pesticides[edit]

See also: Paraquat § Parkinson's_disease, and Rotenone § Parkinson's_disease

Evidence from epidemiological, animal, and in vitro studies suggests that exposure to pesticides increases the risk for Parkinson's disease.[7] One meta-analysis found a risk ratio of 1.6 for ever being exposed to a pesticide, with herbicides and insecticides showing the most risk.[7][44] Rural living, well-drinking, and farming were also associated with Parkinson's, which may be partly explained by pesticide exposure.[44] These factors are pertinent to many communities, one of them being South Asian populations. Organochlorine pesticides (which include DDT) have received the most attention, with several studies reporting that exposure to such pesticides is associated with a doubling of risk for Parkinson's.[7]

Carbon disulfide is a risk factor, and has been identified in industrial worker case studies and has induced parkinsonism in mice.[non-primary source needed][45] It is mainly used in the manufacture of viscose rayon, cellophane film, rubber and carbon tetrachloride.[46]

Metals[edit]

See also: Lead poisoning, Manganism, and Manganese

Lead, which was used in gasoline until 1995 and paint until 1978, is known to damage the nervous system in various ways.[7] A few studies have found that people with high levels of lead in their body had twice the risk of Parkinson's disease.[7] Epidemiological studies on lead, however, have found little evidence for a link with Parkinson's.[7] Iron has been implicated in the etiology of Parkinson's disease, but there is no strong evidence that environmental exposure to it is associated with Parkinson's.[7]

Solvent[edit]

Air pollution[edit]

See also: Particulates

Head injuries[edit]

A 2012 study suggests that players in the National Football League are three times more likely to die from neurodegenerative diseases, including Alzheimer's and Parkinson's diseases, than the general US population.[43] A 2018 study found 56% increase in risk of Parkinson's disease among US military veterans suffered traumatic brain injury.[42]

Exercise[edit]

While many environmental factors may exacerbate Parkinson's disease, exercise is considered to be one of the main protective factors for neurodegenerative disorders, including Parkinson's disease. The types of exercise interventions that have been studied can be categorized as either aerobic or goal-based.[47] Aerobic exercise includes physical activity that increases the heart rate. Aerobic exercise is beneficial to the overall brain through mechanisms that promote neuroplasticity, or the rewiring of the brain circuitry.[47] Goal-based exercises are often developed with the guidance of a physical therapist to use movement to improve motor task performance and enhance motor learning.[47] While exercise has consistently been shown to be beneficial, the optimal interventional benefit is still being researched.[48]

Caffeine consumption[edit]

Smokers and nonsmokers with different rates of caffeine consumption were monitored for their susceptibility to PD. The results indicate that higher coffee/caffeine intake is associated with a significantly lower incidence of PD and that this effect appeared to be independent of smoking.[49]

Environmental-Genetic factors[edit]

Polymorphism of CYP2D6 gene and pesticide exposure[edit]

The CYP2D6 gene is primarily expressed in the liver and is responsible for the enzyme cytochrome P450 2D6. A study showed that those who had a mutation of this gene and were exposed to pesticides were twice as likely to develop Parkinson's Disease; those that had the mutation and were not exposed to pesticides were not found to be at an increased risk of developing PD; the pesticides only had a "modest effect" for those without the mutation of the gene.[31][50]

See also[edit]

References[edit]

  1. ^ Kouli A, Torsney KM, Kuan WL (2018-12-22). "Parkinson's Disease: Etiology, Neuropathology, and Pathogenesis". Parkinson's Disease: Pathogenesis and Clinical Aspects. Codon Publications. p. 3–26. doi:10.15586/codonpublications.parkinsonsdisease.2018.ch1. ISBN 978-0-9944381-6-4. PMID 30702842.
  2. ^ Braak H, Rub U, Gai WP, Del Tredici K (2003-05-01). "Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen". Journal of Neural Transmission. 110 (5): 517–536. doi:10.1007/s00702-002-0808-2. ISSN 0300-9564. PMID 12721813. S2CID 26635560.
  3. ^ Forno LS (1996). "Neuropathology of Parkinsonʼs Disease". Journal of Neuropathology and Experimental Neurology. 55 (3). Oxford University Press (OUP): 259–272. doi:10.1097/00005072-199603000-00001. ISSN 0022-3069. PMID 8786384. S2CID 6289469.
  4. ^ Bhat S, Acharya UR, Hagiwara Y, Dadmehr N, Adeli H (2018). "Parkinson's disease: Cause factors, measurable indicators, and early diagnosis". Computers in Biology and Medicine. 102. Elsevier BV: 234–241. doi:10.1016/j.compbiomed.2018.09.008. ISSN 0010-4825. PMID 30253869. S2CID 52825532.
  5. ^ Oczkowska A, Kozubski W, Lianeri M, Dorszewska J (2014). "Mutations in PRKN and SNCA Genes Important for the Progress of Parkinson's Disease". Current Genomics. 14 (8). Bentham Science Publishers Ltd.: 502–517. doi:10.2174/1389202914666131210205839. ISSN 1389-2029. PMC 3924246. PMID 24532983.
  6. ^ Nuytemans K, Theuns J, Cruts M, Van Broeckhoven C (2010-05-18). "Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update". Human Mutation. 31 (7): 763–780. doi:10.1002/humu.21277. PMC 3056147. PMID 20506312.
  7. ^ a b c d e f g h i Goldman SM (2014). "Environmental toxins and Parkinson's disease". Annual Review of Pharmacology and Toxicology. 54: 141–164. doi:10.1146/annurev-pharmtox-011613-135937. PMID 24050700.
  8. ^ Samii A, Nutt JG, Ransom BR (May 2004). "Parkinson's disease". Lancet. 363 (9423): 1783–1793. doi:10.1016/S0140-6736(04)16305-8. PMID 15172778. S2CID 35364322.
  9. ^ a b c d e f g h i j k Lesage S, Brice A (April 2009). "Parkinson's disease: from monogenic forms to genetic susceptibility factors". Human Molecular Genetics. 18 (R1): R48–R59. doi:10.1093/hmg/ddp012. PMID 19297401.
  10. ^ Correddu D, Leung IK (June 2019). "Targeting mRNA translation in Parkinson's disease". Drug Discovery Today. 24 (6): 1295–1303. doi:10.1016/j.drudis.2019.04.003. PMID 30974176. S2CID 109939167.
  11. ^ Zhou ZD, Selvaratnam T, Lee JC, Chao YX, Tan EK (February 2019). "Molecular targets for modulating the protein translation vital to proteostasis and neuron degeneration in Parkinson's disease". Translational Neurodegeneration. 8: 6. doi:10.1186/s40035-019-0145-0. PMC 6360798. PMID 30740222.
  12. ^ Larsen SB, Hanss Z, Krüger R (July 2018). "The genetic architecture of mitochondrial dysfunction in Parkinson's disease". Cell and Tissue Research. 373 (1): 21–37. doi:10.1007/s00441-017-2768-8. PMC 6015629. PMID 29372317.
  13. ^ Davie CA (2008). "A review of Parkinson's disease". British Medical Bulletin. 86 (1): 109–127. doi:10.1093/bmb/ldn013. PMID 18398010.
  14. ^ Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, et al. (April 1998). "Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism". Nature. 392 (6676): 605–608. Bibcode:1998Natur.392..605K. doi:10.1038/33416. PMID 9560156. S2CID 4432261.
  15. ^ Neumann J, Bras J, Deas E, O'Sullivan SS, Parkkinen L, Lachmann RH, et al. (July 2009). "Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease". Brain. 132 (Pt 7): 1783–1794. doi:10.1093/brain/awp044. PMC 2702833. PMID 19286695.
  16. ^ a b c Davie CA (2008). "A review of Parkinson's disease". British Medical Bulletin. 86: 109–127. doi:10.1093/bmb/ldn013. PMID 18398010.
  17. ^ Puschmann A (September 2017). "New Genes Causing Hereditary Parkinson's Disease or Parkinsonism". Current Neurology and Neuroscience Reports. 17 (9): 66. doi:10.1007/s11910-017-0780-8. PMC 5522513. PMID 28733970.
  18. ^ Deng H, Wang P, Jankovic J (March 2018). "The genetics of Parkinson disease". Ageing Research Reviews. 42: 72–85. doi:10.1016/j.arr.2017.12.007. PMID 29288112. S2CID 28246244.
  19. ^ Quadri M, Mandemakers W, Grochowska MM, Masius R, Geut H, Fabrizio E, et al. (July 2018). "LRP10 genetic variants in familial Parkinson's disease and dementia with Lewy bodies: a genome-wide linkage and sequencing study". The Lancet. Neurology. 17 (7): 597–608. doi:10.1016/s1474-4422(18)30179-0. PMID 29887161. S2CID 47009438.
  20. ^ Chen Y, Cen Z, Zheng X, Pan Q, Chen X, Zhu L, et al. (June 2019). "LRP10 in autosomal-dominant Parkinson's disease". Movement Disorders. 34 (6): 912–916. doi:10.1002/mds.27693. PMID 30964957. S2CID 106408549.
  21. ^ Dhungel N, Eleuteri S, Li LB, Kramer NJ, Chartron JW, Spencer B, et al. (January 2015). "Parkinson's disease genes VPS35 and EIF4G1 interact genetically and converge on α-synuclein". Neuron. 85 (1): 76–87. doi:10.1016/j.neuron.2014.11.027. PMC 4289081. PMID 25533483.
  22. ^ a b Martin I, Dawson VL, Dawson TM (Sep 2011). "Recent advances in the genetics of Parkinson's disease". Annual Review of Genomics and Human Genetics. 12 (10): 301–325. doi:10.1146/annurev-genom-082410-101440. PMC 4120236. PMID 21639795.
  23. ^ Funayama M, Hasegawa K, Kowa H, Saito M, Tsuji S, Obata F (March 2002). "A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1". Annals of Neurology. 51 (3): 296–301. doi:10.1002/ana.10113. PMID 11891824. S2CID 10360790.
  24. ^ a b Chen-Plotkin AS, Martinez-Lage M, Sleiman PM, Hu W, Greene R, Wood EM, et al. (April 2011). "Genetic and clinical features of progranulin-associated frontotemporal lobar degeneration". Archives of Neurology. 68 (4): 488–497. doi:10.1001/archneurol.2011.53. PMC 3160280. PMID 21482928.
  25. ^ Nalls MA, Plagnol V, Hernandez DG, Sharma M, Sheerin UM, Saad M, et al. (February 2011). "Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies". Lancet. 377 (9766): 641–649. doi:10.1016/S0140-6736(10)62345-8. PMC 3696507. PMID 21292315.
  26. ^ a b c Sidransky E, Lopez G (November 2012). "The link between the GBA gene and parkinsonism". The Lancet. Neurology. 11 (11): 986–998. doi:10.1016/S1474-4422(12)70190-4. PMC 4141416. PMID 23079555.
  27. ^ a b c d e f Wood-Kaczmar A, Gandhi S, Wood NW (November 2006). "Understanding the molecular causes of Parkinson's disease". Trends in Molecular Medicine. 12 (11): 521–528. doi:10.1016/j.molmed.2006.09.007. PMID 17027339.
  28. ^ Cookson MR (2005). "The biochemistry of Parkinson's disease". Annual Review of Biochemistry. 74: 29–52. doi:10.1146/annurev.biochem.74.082803.133400. PMID 15952880.
  29. ^ a b "SNCA". Genetics Home Reference. U.S. National Library of Medicine. Retrieved 2016-08-16. Genomic Location: The SNCA gene is found on chromosome 4.
  30. ^ a b "SNCA". Genetics Home Reference. U.S. National Library of Medicine. Retrieved 2016-08-16.
  31. ^ a b Tsuboi Y (September 2012). "Environmental-genetic interactions in the pathogenesis of Parkinson's disease". Experimental Neurobiology. 21 (3): 123–128. doi:10.5607/en.2012.21.3.123. PMC 3454809. PMID 23055790.
  32. ^ Lesage S, Brice A (April 2009). "Parkinson's disease: from monogenic forms to genetic susceptibility factors". Human Molecular Genetics. 18 (R1): R48–R59. doi:10.1093/hmg/ddp012. PMID 19297401.
  33. ^ Teismann P, Schulz JB (October 2004). "Cellular pathology of Parkinson's disease: astrocytes, microglia and inflammation". Cell and Tissue Research. 318 (1): 149–161. doi:10.1007/s00441-004-0944-0. PMID 15338271. S2CID 19101756.
  34. ^ Thompson SJ, Loftus LT, Ashley MD, Meller R (February 2008). "Ubiquitin-proteasome system as a modulator of cell fate". Current Opinion in Pharmacology. 8 (1): 90–95. doi:10.1016/j.coph.2007.09.010. PMC 2265078. PMID 17981502.
  35. ^ a b Kim SY, Seong MW, Jeon BS, Kim SY, Ko HS, Kim JY, et al. (July 2012). "Phase analysis identifies compound heterozygous deletions of the PARK2 gene in patients with early-onset Parkinson disease". Clinical Genetics. 82 (1): 77–82. doi:10.1111/j.1399-0004.2011.01693.x. PMID 21534944. S2CID 36434515.
  36. ^ Leroy E, Boyer R, Auburger G, Leube B, Ulm G, Mezey E, et al. (October 1998). "The ubiquitin pathway in Parkinson's disease". Nature. 395 (6701): 451–452. Bibcode:1998Natur.395..451L. doi:10.1038/26652. PMID 9774100. S2CID 204997455.
  37. ^ a b Hatano Y, Li Y, Sato K, Asakawa S, Yamamura Y, Tomiyama H, et al. (September 2004). "Novel PINK1 mutations in early-onset parkinsonism". Annals of Neurology. 56 (3): 424–427. doi:10.1002/ana.20251. PMID 15349870. S2CID 10853835.
  38. ^ a b Bonifati V, Rizzu P, van Baren MJ, Schaap O, Breedveld GJ, Krieger E, et al. (January 2003). "Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism". Science. 299 (5604): 256–259. doi:10.1126/science.1077209. PMID 12446870. S2CID 27186691.
  39. ^ "LRRK2". GeneCards. Rehovot, Israel: Weizmann Institute of Science. Retrieved 2016-08-16.
  40. ^ Hernandez D, Paisan Ruiz C, Crawley A, Malkani R, Werner J, Gwinn-Hardy K, et al. (December 2005). "The dardarin G 2019 S mutation is a common cause of Parkinson's disease but not other neurodegenerative diseases". Neuroscience Letters. 389 (3): 137–139. doi:10.1016/j.neulet.2005.07.044. PMID 16102903. S2CID 33750441.
  41. ^ Haugarvoll K, Wszolek ZK (December 2009). "Clinical features of LRRK2 parkinsonism". Parkinsonism & Related Disorders. 15 (Suppl 3): S205–S208. doi:10.1016/S1353-8020(09)70815-6. PMID 20082991.
  42. ^ a b Gardner RC, Byers AL, Barnes DE, Li Y, Boscardin J, Yaffe K (May 2018). "Mild TBI and risk of Parkinson disease: A Chronic Effects of Neurotrauma Consortium Study". Neurology. 90 (20): e1771–e1779. doi:10.1212/WNL.0000000000005522. PMC 5957305. PMID 29669907.
  43. ^ a b Lehman EJ, Hein MJ, Baron SL, Gersic CM (November 2012). "Neurodegenerative causes of death among retired National Football League players". Neurology. 79 (19): 1970–1974. doi:10.1212/WNL.0b013e31826daf50. PMC 4098841. PMID 22955124.
  44. ^ a b Noyce AJ, Bestwick JP, Silveira-Moriyama L, Hawkes CH, Giovannoni G, Lees AJ, et al. (December 2012). "Meta-analysis of early nonmotor features and risk factors for Parkinson disease". Annals of Neurology. 72 (6): 893–901. doi:10.1002/ana.23687. PMC 3556649. PMID 23071076.
  45. ^ Zu L (2023). "Chronic carbon disulfide exposure induces parkinsonian pathology via a-synuclein aggregation and necrosome complex interaction". iScience. 26 (10): 1–16. doi:10.1016/j.isci.2023.107787. PMC 10507234. PMID 37731606.
  46. ^ "Carbon Disulfide". CDC. 2 Nov 2018. Retrieved 3 Dec 2023.
  47. ^ a b c Petzinger GM, Fisher BE, McEwen S, Beeler JA, Walsh JP, Jakowec MW (July 2013). "Exercise-enhanced neuroplasticity targeting motor and cognitive circuitry in Parkinson's disease". The Lancet. Neurology. 12 (7): 716–726. doi:10.1016/S1474-4422(13)70123-6. PMC 3690528. PMID 23769598.
  48. ^ Goodwin VA, Richards SH, Taylor RS, Taylor AH, Campbell JL (April 2008). "The effectiveness of exercise interventions for people with Parkinson's disease: a systematic review and meta-analysis". Movement Disorders. 23 (5): 631–640. doi:10.1002/mds.21922. hdl:10871/17451. PMID 18181210. S2CID 3808899.
  49. ^ Tsuboi Y (September 2012). "Environmental-genetic interactions in the pathogenesis of Parkinson's disease". Experimental Neurobiology. 21 (3): 123–128. doi:10.5607/en.2012.21.3.123. PMC 3454809. PMID 23055790.
  50. ^ Elbaz A, Levecque C, Clavel J, Vidal JS, Richard F, Amouyel P, et al. (March 2004). "CYP2D6 polymorphism, pesticide exposure, and Parkinson's disease". Annals of Neurology. 55 (3): 430–434. doi:10.1002/ana.20051. PMID 14991823. S2CID 19772933.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Causes_of_Parkinson%27s_disease&oldid=1210259531"